Related references
Note: Only part of the references are listed.Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Lydia Meder et al.
CANCER RESEARCH (2018)
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins et al.
LANCET ONCOLOGY (2018)
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
Jacqueline Vuky et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) Abstracts
[Anonymous]
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Improving immune-vascular crosstalk for cancer immunotherapy
Yuhui Huang et al.
NATURE REVIEWS IMMUNOLOGY (2018)
An early history of T cell-mediated cytotoxicity
Pierre Golstein et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Regulatory mechanisms in T cell receptor signalling
Guillaume Gaud et al.
NATURE REVIEWS IMMUNOLOGY (2018)
A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.
Daniel Peter Petrylak et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung-Min Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Jun Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Roderik M. Kortlever et al.
CELL (2017)
PD-1 and PD-L1 antibodies in cancer: current status and future directions
Arjun Vasant Balar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan et al.
ANGIOGENESIS (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2016)
The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
Weilan Ye
DEVELOPMENTAL CELL (2016)
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
S. Percy Ivy et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Antiangiogenic therapy in oncology: current status and future directions
Gordon C. Jayson et al.
LANCET (2016)
The Role of the Tumor vasculature in the Host immune Response: implications for Therapeutic Strategies Targeting the Tumor Microenvironment
Shona A. Hendry et al.
FRONTIERS IN IMMUNOLOGY (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M. Tolaney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
PD-L1 expression in nonclear-cell renal cell carcinoma
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2014)
The Role of Mechanical Forces in Tumor Growth and Therapy
Rakesh K. Jain et al.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 16 (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dawn E. Dolan et al.
CANCER CONTROL (2014)
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
VEGFA and tumour angiogenesis
L. Claesson-Welsh et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Immunological checkpoint inhibitors enter adolescence
Anna K. Nowak
LANCET ONCOLOGY (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Bevacizumab and ovarian cancer
Agustin Garcia et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2013)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
Eric Tartour et al.
CANCER AND METASTASIS REVIEWS (2011)
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson et al.
CLINICAL CANCER RESEARCH (2011)
Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications
Katrien De Bock et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2011)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2-Dependent Angiogenesis without Affecting Ligand Binding
Jane Kendrew et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C. Bible et al.
LANCET ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance (vol 206, pg 421, 2009)
F. Fallarino et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Hypoxia: A key regulator of angiogenesis in cancer
Debbie Liao et al.
CANCER AND METASTASIS REVIEWS (2007)
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
R. Houston Thompson et al.
CLINICAL CANCER RESEARCH (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Identification of the genes for kidney cancer: Opportunity for disease-specific targeted therapeutics
W. Marston Linehan et al.
CLINICAL CANCER RESEARCH (2007)
Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo
Simon Read et al.
JOURNAL OF IMMUNOLOGY (2006)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson et al.
CANCER RESEARCH (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
N Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metal loproteinases
F Winkler et al.
CANCER CELL (2004)
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
JM Chemnitz et al.
JOURNAL OF IMMUNOLOGY (2004)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Tumorigenesis and the angiogenic switch
G Bergers et al.
NATURE REVIEWS CANCER (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
The interaction properties of costimulatory molecules revisited
AV Collins et al.
IMMUNITY (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
JG Egen et al.
IMMUNITY (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not T(H)2 cytokines
LP Kane et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Structural analysis of CTLA-4 function in vivo
EL Masteller et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
